Sorafenib in advanced iodine-refractory differentiated thyroid cancer: Efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET
Sorafenib in advanced iodine-refractory differentiated thyroid cancer: Efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET(460 views) Marotta V, Ramundo V, Camera L, Del Prete M, Fonti R, Esposito R, Palmieri G, Salvatore M, Vitale M, Colao A, Faggiano A
Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Via S. Pansini 5, 80131 Napoli, Italy
Department of Biomorphological and Functional Sciences, Federico II University of Naples, Naples, Italy
Department of Medicine and Surgery, University of Salerno, Baronissi, Italy
National Cancer Institute, Fondazione G. Pascale, Naples, Italy
Molecular Mechanisms Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Scientific Directorate, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
References: Jemal, A., Siegel, R., Xu, J., Cancer statistics (2010) CA: A Cancer Journal for Clinicians, 60, pp. 277-30
Yu, G.P., Li, J.C., Branovan, D., Thyroid cancer incidence and survival in the national cancer institute surveillance, epidemiology, and end results race/ethnicity groups (2010) Thyroid, 20, pp. 465-473
Cooper, D.S., Doherty, G.M., Haugen, B.R., Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer (2009) Thyroid, 19, pp. 1167-1214
Schlumberger, M.J., Papillary and follicular thyroid carcinoma (1998) New England Journal of Medicine, 338, pp. 297-306
Eustatia-Rutten, C.F., Corssmit, E.P., Biermasz, N.R., Survival and death causes in differentiated thyroid carcinoma (2006) Journal of Clinical Endocrinology and Metabolism, 91, pp. 313-319
Hay, I.D., Thompson, G.B., Grant, C.S., Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): Temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients (2002) World Journal of Surgery, 26, pp. 879-885
Durante, C., Haddy, N., Baudin, E., Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy (2006) Journal of Clinical Endocrinology and Metabolism, 91, pp. 2892-2899
Sherman, S.I., Early clinical studies of novel therapies for thyroid cancers (2008) Endocrinology and Metabolism Clinics of North America, 37, pp. 511-524. , xi
Cohen, Y., Xing, M., Mambo, E., BRAF mutation in papillary thyroid carcinoma (2003) Journal of the National Cancer Institute, 95, pp. 625-627
Santoro, M., Melillo, R.M., Fusco, A., RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture (2006) European Journal of Endocrinology, 155, pp. 645-653
Nikiforova, M.N., Lynch, R.A., Biddinger, P.W., RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: Evidence for distinct molecular pathways in thyroid follicular carcinoma (2003) Journal of Clinical Endocrinology and Metabolism, 88, pp. 2318-2326
Carlomagno, F., Anaganti, S., Guida, T., BAY 43-9006 inhibition of oncogenic RET mutants (2006) Journal of the National Cancer Institute, 98, pp. 326-334
Ferrara, N., VEGF and the quest for tumour angiogenesis factors (2002) Nature Reviews Cancer, 2, pp. 795-803
Eisenhauer, E.A., Therasse, P., Bogaerts, J., New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) (2009) European Journal of Cancer, 45, pp. 228-247
Oken, M.M., Creech, R.H., Tormey, D.C., Toxicity and response criteria of the Eastern Cooperative Oncology Group (1982) American Journal of Clinical Oncology, 5, pp. 649-655
Shankar, L.K., Hoffman, J.M., Bacharach, S., Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials (2006) Journal of Nuclear Medicine, 47, pp. 1059-1066
Therasse, P., Arbuck, S.G., Eisenhauer, E.A., New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada (2000) Journal of the National Cancer Institute, 92, pp. 205-216
Ahmed, M., Barbachano, Y., Riddell, A., Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: A phase II study in a UK based population (2011) European Journal of Endocrinology, 165, pp. 315-322
Capdevila, J., Iglesias, L., Halperin, I., Sorafenib in metastatic thyroid cancer (2012) Endocrine-Related Cancer, 19, pp. 209-216
Gupta-Abramson, V., Troxel, A.B., Nellore, A., Phase II trial of sorafenib in advanced thyroid cancer (2008) Journal of Clinical Oncology, 26, pp. 4714-4719
Kloos, R.T., Ringel, M.D., Knopp, M.V., Phase II trial of sorafenib in metastatic thyroid cancer (2009) Journal of Clinical Oncology, 27, pp. 1675-1684
Cabanillas, M.E., Waguespack, S.G., Bronstein, Y., Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: The M. D. Anderson experience (2010) Journal of Clinical Endocrinology and Metabolism, 95, pp. 2588-2595
Hoftijzer, H., Heemstra, K.A., Morreau, H., Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma (2009) European Journal of Endocrinology, 161, pp. 923-931
Choi, H., Charnsangavej, C., Faria, S.C., Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria (2007) Journal of Clinical Oncology, 25, pp. 1753-1759
Faivre, S., Zappa, M., Vilgrain, V., Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib (2011) Clinical Cancer Research, 17, pp. 4504-4512
Kilickap, S., Abali, H., Celik, I., Bevacizumab, bleeding, thrombosis, and warfarin (2003) Journal of Clinical Oncology, 21, p. 3542. , author reply 3
Zangari, M., Fink, L.M., Elice, F., Thrombotic events in patients with cancer receiving antiangiogenesis agents (2009) Journal of Clinical Oncology, 27, pp. 4865-4873
Kamba, T., McDonald, D.M., Mechanisms of adverse effects of anti-VEGF therapy for cancer (2007) British Journal of Cancer, 96, pp. 1788-1795
Peters, N.A., Richel, D.J., Verhoeff, J.J., Bowel perforation after radiotherapy in a patient receiving sorafenib (2008) Journal of Clinical Oncology, 26, pp. 2405-2406
Basille, D., Andrejak, M., Bentayeb, H., Bronchial fistula associated with sunitinib in a patient previously treated with radiation therapy (2010) Annals of Pharmacotherapy, 44, pp. 383-386
Force, T., Krause, D.S., Van Etten, R.A., Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition (2007) Nature Reviews Cancer, 7, pp. 332-344
Yamaguchi, O., Watanabe, T., Nishida, K., Cardiac-specific disruption of the c-raf-1 gene induces cardiac dysfunction and apoptosis (2004) The Journal of Clinical Investigation, 114, pp. 937-943
Cabanillas, M.E., Hu, M.I., Durand, J.B., Challenges associated with tyrosine kinase inhibitor therapy for metastatic thyroid cancer (2011) Journal of Thyroid Research, 2011, p. 985780
Izumiya, Y., Shiojima, I., Sato, K., Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload (2006) Hypertension, 47, pp. 887-893
Maitland, M.L., Bakris, G.L., Black, H.R., Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors (2010) Journal of the National Cancer Institute, 102, pp. 596-604
Schmidinger, M., Zielinski, C.C., Vogl, U.M., Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma (2008) Journal of Clinical Oncology, 26, pp. 5204-5212
Prior, J.O., Montemurro, M., Orcurto, M.V., Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor (2009) Journal of Clinical Oncology, 27, pp. 439-445
Vercellino, L., Bousquet, G., Baillet, G., 18F-FDG PET/CT imaging for an early assessment of response to sunitinib in metastatic renal carcinoma: Preliminary study (2009) Cancer Biotherapy and Radiopharmaceuticals, 24, pp. 137-144
Carr, L.L., Mankoff, D.A., Goulart, B.H., Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation (2010) Clinical Cancer Research, 16, pp. 5260-5268
Yu, G. P., Li, J. C., Branovan, D., Thyroid cancer incidence and survival in the national cancer institute surveillance, epidemiology, and end results race/ethnicity groups (2010) Thyroid, 20, pp. 465-473
Cooper, D. S., Doherty, G. M., Haugen, B. R., Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer (2009) Thyroid, 19, pp. 1167-1214
Schlumberger, M. J., Papillary and follicular thyroid carcinoma (1998) New England Journal of Medicine, 338, pp. 297-306
Hay, I. D., Thompson, G. B., Grant, C. S., Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): Temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients (2002) World Journal of Surgery, 26, pp. 879-885
Sherman, S. I., Early clinical studies of novel therapies for thyroid cancers (2008) Endocrinology and Metabolism Clinics of North America, 37, pp. 511-524. , xi
Nikiforova, M. N., Lynch, R. A., Biddinger, P. W., RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: Evidence for distinct molecular pathways in thyroid follicular carcinoma (2003) Journal of Clinical Endocrinology and Metabolism, 88, pp. 2318-2326
Eisenhauer, E. A., Therasse, P., Bogaerts, J., New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1. 1) (2009) European Journal of Cancer, 45, pp. 228-247
Oken, M. M., Creech, R. H., Tormey, D. C., Toxicity and response criteria of the Eastern Cooperative Oncology Group (1982) American Journal of Clinical Oncology, 5, pp. 649-655
Shankar, L. K., Hoffman, J. M., Bacharach, S., Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials (2006) Journal of Nuclear Medicine, 47, pp. 1059-1066
Kloos, R. T., Ringel, M. D., Knopp, M. V., Phase II trial of sorafenib in metastatic thyroid cancer (2009) Journal of Clinical Oncology, 27, pp. 1675-1684
Cabanillas, M. E., Waguespack, S. G., Bronstein, Y., Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: The M. D. Anderson experience (2010) Journal of Clinical Endocrinology and Metabolism, 95, pp. 2588-2595
Peters, N. A., Richel, D. J., Verhoeff, J. J., Bowel perforation after radiotherapy in a patient receiving sorafenib (2008) Journal of Clinical Oncology, 26, pp. 2405-2406
Maitland, M. L., Bakris, G. L., Black, H. R., Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors (2010) Journal of the National Cancer Institute, 102, pp. 596-604
Prior, J. O., Montemurro, M., Orcurto, M. V., Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor (2009) Journal of Clinical Oncology, 27, pp. 439-445
Carr, L. L., Mankoff, D. A., Goulart, B. H., Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation (2010) Clinical Cancer Research, 16, pp. 5260-5268
Sorafenib in advanced iodine-refractory differentiated thyroid cancer: Efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET
Sorafenib in advanced iodine-refractory differentiated thyroid cancer: Efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET
Sorafenib in advanced iodine-refractory differentiated thyroid cancer: Efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET
Bruni AC, Bernardi L, Colao R, Rubino E, Smirne N, Frangipane F, Terni B, Curcio SA, Mirabelli M, Clodomiro A, Di Lorenzo R, Maletta R, Anfossi M, Gallo M, Geracitano S, Tomaino C, Muraca MG, Leotta A, Lio SG, Pinessi L, Rainero I, Sorbi S, Nee L, Milan G, Pappata S, Postiglione A, Abbamondi N, Forloni G, St George Hyslop P, Rogaeva E, Bugiani O, Giaccone G, Foncin JF, Spillantini MG, Puccio G * Worldwide distribution of PSEN1 Met146Leu mutation: A large variability for a founder mutation(972 views) Neurology (ISSN: 0028-3878, 1526-632x, 1526-632xelectronic), 2010 Mar 9; 74(10): 798-806. Impact Factor:8.017 ViewExport to BibTeXExport to EndNote